FDA adds a boxed warning to ferric carboxymaltose prescribing information, emphasizing severe low phosphate risks and mandatory monitoring protocols.
Significant improvement seen in self-reported brain fog, concentration, working memory, processing speed, verbal memory, problem solving.
The phase 3 REMODEL-1/-2 trials demonstrated the superiority of remibrutinib vs teriflunomide in reducing annualized relapse rate in RMS patients.
HealthDay News — Lower adherence to blood pressure-lowering medication is associated with no benefit for preventing cardiovascular events, according to a study presented at the annual meeting of the ...
HealthDay News — Unintentional ingestion of recreational drugs increased substantially in US children younger than 6 years of age from 2000 to 2024, according to a study published online June 24 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results